Quick search:
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer | NEJM
2 Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination | NEJM
3 Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 | NEJM
4 SARS-CoV-2 Vaccine–Induced Immune Thrombotic Thrombocytopenia | NEJM
5 Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center | NEJM
6 Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination | NEJM
7 Covid-19 and the Investigator Pipeline
8 Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas | NEJM
9 Sunken Nose
10 New England Journal of Medicine publishes exploratory study showing signals of positive activity in COMP360 psilocybin compared with escitalopram for major depressive disorder
11 BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers | NEJM
12 Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization
13 Preparing for the Future — Nanobodies for Covid-19? | NEJM
14 Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2 | NEJM
15 SARS-CoV-2 Antibody Response in Persons with Past Natural Infection | NEJM
16 Obesity, Immunity, and Cancer
17 Health Care Worker Strikes and the Covid Pandemic | NEJM
18 Leveraging Open Science to Accelerate Research
19 Beyond the Rubble of Lake Street — Minds in Crisis in a City in Crisis
20 Vancomycin Infusion Reaction — Moving beyond “Red Man Syndrome” | NEJM
21 Stalking the Diagnosis | NEJM
22 SARS-CoV-2 Infection after Vaccination in Health Care Workers in California | NEJM
23 Addressing Workforce Diversity — A Quality-Improvement Framework | NEJM
24 New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications | NEJM
25 Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351) | NEJM
26 “Vaccine Passport” Certification — Policy and Ethical Considerations | NEJM
27 On the Shoulders of Giants — From Jenner's Cowpox to mRNA Covid Vaccines
28 New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with Pulmonary Arterial Hypertension
29 Antibody Mediated Prevention (AMP) trials data published by the New England Journal of Medicine
30 Addressing Vaccine Hesitancy in BIPOC Communities — Toward Trustworthiness, Partnership, and Reciprocity
31 New England Journal of Medicine Includes Dallas Hospital Employees in Data in Recent Article
32 Combating Anti-Asian Sentiment — A Practical Guide for Clinicians
33 Breathless
34 Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 | NEJM
35 Medicare's New Device-Coverage Pathway — Breakthrough or Breakdown? | NEJM
36 Donanemab in Early Alzheimer's Disease
37 Dying in a Leadership Vacuum
38 Hydroxychloroquine in Hospitalized Patients with Covid-19 –
39 Without Sanctuary
40 SARS-CoV-2 Transmission among Marine Recruits during Quarantine | NEJM
41 Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 | NEJM
42 Failed Assignments — Rethinking Sex Designations on Birth Certificates | NEJM
43 Neutralizing Activity of BNT162b2-Elicited Serum
44 Covid-19 Vaccine Resources
45 A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19 | NEJM
46 Microvascular Injury in the Brains of Patients with Covid-19
47 Once-Weekly Semaglutide in Adults with Overweight or Obesity | NEJM
48 A New Vaccine to Battle Covid-19 | NEJM
49 Case 30-2020: A 54-Year-Old Man with Sudden Cardiac Arrest
50 One of Us
51 Ascaris in the Stomach | NEJM
52 New NEJM article can serve as diabetes medication resource
53 BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting | NEJM
54 Once-Daily Semaglutide Promising for Treating Severe Nonalcoholic Fatty Liver Disease
55 Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine | NEJM
56 Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
57 Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers | NEJM
58 Universal Masking in the Covid-19 Era | NEJM
59 Corneal Bee Sting
60 The Inequity of Isolation
61 Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
62 Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine | NEJM
63 Blood Clots After COVID-19 Vaccination Linked to Immune Response: UK Report
64 Private Equity and Physician Medical Practices — Navigating a Changing Ecosystem
65 A Pulsating Leg | NEJM
66 Bartonella Neuroretinitis
67 A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia | NEJM
68 Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621.
69 A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19 | NEJM
70 The Gift | NEJM
71 Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
72 Beyond Politics — Promoting Covid-19 Vaccination in the United States | NEJM
73 COVID-19 Scan for Apr 16, 2021
74 Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality | NEJM
75 In a First, New England Journal of Medicine Joins Never-Trumpers
76 Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma | NEJM
77 The Stress of Bayesian Medicine — Uncomfortable Uncertainty in the Face of Covid-19 | NEJM
78 Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia | NEJM
79 The FDA and the Importance of Trust
80 KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
81 The New Stability | NEJM
82 Analysis of diversity at premier medical journals met with silence
83 Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
84 Remdesivir for the Treatment of Covid-19 — Final Report | NEJM
85 Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19 | NEJM
86 Misrepresenting Race — The Role of Medical Schools in Propagating Physician Bias | NEJM
87 Telemedicine and Medical Licensure — Potential Paths for Reform
88 Telephone | NEJM
89 Hydroxychloroquine with or without Azithromycin in Covid-19 | NEJM
90 Health Policy in a Biden Administration
91 Editorial The Covid-19 Vaccine-Development Multiverse
92 A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 | NEJM
93 Facial Masking for Covid-19 — Potential for “Variolation” as We Await a Vaccine | NEJM
94 Covid-19 — A Reminder to Reason
95 Plans and Pandemics
96 In Pursuit of PPE
97 Injuries from Less-Lethal Weapons during the George Floyd Protests in Minneapolis | NEJM
98 Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results | NEJM
99 Study Finds Magic Mushrooms May Help Fight Depression
100 Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine | NEJM